Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment-naive CD30-positive mature T-cell and NK-cell neoplasms, including systemic anaplastic large cell lymphoma~* Measurable disease of at least 1.5 cm~* ECOG performance status less than or equal to 2~Exclusion Criteria:~* Known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy~* Current diagnosis of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, Sezary syndrome or other primary cutaneous lymphomas; extranodal NK/T-cell lymphoma, nasal type~* History of another primary malignancy that has not been in remission for at least 3 years~* Left ventricular ejection fraction \<45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months~* Viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin~* Known human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus positive status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Sequential
- 2 (Type: EXPERIMENTAL): Combination
- 3 Brentuximab vedotin/CH-P (Type: EXPERIMENTAL): Combination

Based on this trial design, predict the completion outcome and termination type (if applicable).